177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life

[11] Leary C(2017)Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors N Engl J Med 376 125-135

[12] Mares JE(2015)Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors Eur J Nucl Med Mol Imaging 42 5-19

[13] Lemelin A(2016)Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience Cancer Biother Radiopharm 31 189-198

[14] Maucort-Boulch D(1992)Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 613-619

[15] Castel-Kremer E(1987)A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 373-383

[16] Forestier J(2018)Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial J Clin Oncol 36 2578-2584

[17] Hervieu V(2013)Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours Br J Cancer 108 301-310

[18] Lorcet M(2016)Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate Eur J Nucl Med Mol Imaging 43 1802-1811

[19] Garcia-Carbonero R(2015)Renal function affects absorbed dose to the kidneys and haematological toxicity during (1)(7)(7)Lu-DOTATATE treatment Eur J Nucl Med Mol Imaging 42 947-955

[20] Capdevila J(2020)Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study Eur J Nucl Med Mol Imaging 47 2372-2382

[11] Leary C(2017)Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors N Engl J Med 376 125-135

[12] Mares JE(2015)Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors Eur J Nucl Med Mol Imaging 42 5-19

[13] Lemelin A(2016)Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience Cancer Biother Radiopharm 31 189-198

[14] Maucort-Boulch D(1992)Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 613-619

[15] Castel-Kremer E(1987)A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 373-383

[16] Forestier J(2018)Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial J Clin Oncol 36 2578-2584

[17] Hervieu V(2013)Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours Br J Cancer 108 301-310

[18] Lorcet M(2016)Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate Eur J Nucl Med Mol Imaging 43 1802-1811

[19] Garcia-Carbonero R(2015)Renal function affects absorbed dose to the kidneys and haematological toxicity during (1)(7)(7)Lu-DOTATATE treatment Eur J Nucl Med Mol Imaging 42 947-955

[20] Capdevila J(2020)Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study Eur J Nucl Med Mol Imaging 47 2372-2382